LeadershipAdvocacy & Gov't AffairsHistoryCareers at Joslin
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseJoslin Clinical GuidelinesOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare Professionals
• Make an AppointmentAdult ClinicPediatricsEye CareWeight Management ProgramsAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationCause MarketingInternationalCommercialization and VenturesHealthcare Professionals
Give NowWays to GiveEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Rene Maehr, Ph.D.

Type 1 diabetes (T1D) is the result of an autoimmune destruction of insulin producing, pancreatic beta cells. The events leading to the disease have usually occurred long before diagnosis and are based on complex interactions between genes and the environment. The currently available rodent models for type 1 diabetes can only represent a limited number of patients leaving open the question how many different types of T1D exist. We propose to model T1D by using key cell populations differentiated from human pluripotent stem cells. To this end, my main research interest lies the generation of an autoimmune prone immune system from patient specific induced pluripotent stem (iPS) cells. The long term goal is to recapitulate the disease in a patient specific manner and to identify novel treatment strategies.

Page last updated: May 14, 2013